* • already received a non-mrna covid-19 vaccine dose (j\&j) * any use in the past 90 days of a monoclonal antibody against covid-19 (e.g., bamlanivimab, casirivimab, imdevimab) * any known contraindication to covid-19 vaccination, including allergic reaction to prior covid-19 vaccination, and severe allergy to vaccine components (e.g., pegloticase) * known hiv/aids or any other immunodeficient condition * use of immunomodulatory therapy for any non-rheumatologic indication (e.g., organ transplantation) * currently receiving radiation or chemotherapy for any type of malignancy. * receipt of any immunization other than covid-19 within two weeks prior to the covid-19 vaccine supplemental dose * significant underlying illness that would be expected to prevent completion of the study (e.g., life-threatening disease likely to limit survival to \< 1 year) * any other reason that, in the opinion of the site investigator, would interfere with required study related evaluations (e.g., uncontrolled disease flare, uncontrolled comorbidity)

* • already received a non-mrna covid-19 vaccine dose (j\&j) * any use in the past 90 days of a monoclonal antibody against covid-19 (e.g., bamlanivimab, casirivimab, imdevimab) * any known contraindication to covid-19 vaccination, including allergic reaction to prior covid-19 vaccination, and severe allergy to vaccine components (e.g., pegloticase) * known hiv/aids or any other immunodeficient condition * use of immunomodulatory therapy for any non-rheumatologic indication (e.g., organ transplantation) * currently receiving radiation or chemotherapy for any type of malignancy. * receipt of any immunization other than covid-19 within two weeks prior to the covid-19 vaccine supplemental dose * significant underlying illness that would be expected to prevent completion of the study (e.g., life-threatening disease likely to limit survival to \< 1 year) * any other reason that, in the opinion of the site investigator, would interfere with required study related evaluations (e.g., uncontrolled disease flare, uncontrolled comorbidity)

- • already received a non-mrna covid-19 vaccine dose (j&j) - any use in the past 90 days of a monoclonal antibody against covid-19 (e.g., bamlanivimab, casirivimab, imdevimab) - any known contraindication to covid-19 vaccination, including allergic reaction to prior covid-19 vaccination, and severe allergy to vaccine components (e.g., pegloticase) - known hiv/aids or any other immunodeficient condition - use of immunomodulatory therapy for any non-rheumatologic indication (e.g., organ transplantation) - currently receiving radiation or chemotherapy for any type of malignancy. - receipt of any immunization other than covid-19 within two weeks prior to the covid-19 vaccine supplemental dose - significant underlying illness that would be expected to prevent completion of the study (e.g., life-threatening disease likely to limit survival to < 1 year) - any other reason that, in the opinion of the site investigator, would interfere with required study related evaluations (e.g., uncontrolled disease flare, uncontrolled comorbidity)

- • already received a non-mrna covid-19 vaccine dose (j&j) - any use in the past 90 days of a monoclonal antibody against covid-19 (e.g., bamlanivimab, casirivimab, imdevimab) - any known contraindication to covid-19 vaccination, including allergic reaction to prior covid-19 vaccination, and severe allergy to vaccine components (e.g., pegloticase) - known hiv/aids or any other immunodeficient condition - use of immunomodulatory therapy for any non-rheumatologic indication (e.g., organ transplantation) - currently receiving radiation or chemotherapy for any type of malignancy. - receipt of any immunization other than covid-19 within two weeks prior to the covid-19 vaccine supplemental dose - significant underlying illness that would be expected to prevent completion of the study (e.g., life-threatening disease likely to limit survival to < 1 year) - any other reason that, in the opinion of the site investigator, would interfere with required study related evaluations (e.g., uncontrolled disease flare, uncontrolled comorbidity)